The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation

Leukemia

Volumn 24, Issue 11, 2010, Pages 1910-1919

  Oancea, C ^a   Ruster B ^a   Henschler, R ^a   Puccetti, E ^b   Ruthardt, M ^a  

^a GOETHE UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

acute myeloid leukemia; DEK CAN; leukemic stem cells; leukemogenesis; t(6; 9)

Indexed keywords

CELL SURFACE MARKER; HYBRID PROTEIN; PROTEIN DEK; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL SUBPOPULATION; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION 6; CHROMOSOME TRANSLOCATION 9; FEMALE; HEMATOPOIETIC STEM CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING;

EID: 78149464734     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.180     Document Type: Article

References (29)

1. Passegué E, Jamieson CHM, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci USA 2003; 100: 11842-11849.
2. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278: 1059-1064.
3. Puccetti E, Obradovic D, Beissert T, Bianchini A, Washburn B, Chiaradonna F et al. AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor. Cancer Res 2002; 62: 7050-7058.
4. Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 2006; 12: 945-949.
5. Zheng X, Beissert T, Kukoc-Zivojnov N, Puccetti E, Altschmied J, Strolz C et al. Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood 2004; 103: 3535-3543.
6. Shearer BM, Knudson RA, Flynn HC, Ketterling RP. Development of a D-FISH method to detect DEK/CAN fusion resulting from t(6;9)(p23;q34) in patients with acute myelogenous leukemia. Leukemia 2005; 19: 126-131.
7. Soekarman D, von Lindern M, van der Plas SDC, Selleri L, Bartram C, Martiat P et al. Dek-can rearrangment in translocation (6;9)(p23;q34). Leukemia 1992; 6: 489-494.
8. Chi Y, Lindgren V, Quigley S, Gaitonde S. Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview. Arch Pathol Lab Med 2008; 132: 1835-1837.
9. Garçon L, Libura M, Delabesse E, Valensi F, Asnafi V, Berger C et al. DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. Leukemia 2005; 19: 1338-1344.
10. von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, Buijs A et al. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol 1992; 12: 1687-1697.
11. Oyarzo MP, Lin P, Glassman A, Bueso-Ramos CE, Luthra R, Medeiros LJ. Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. Am J Clin Pathol 2004; 122: 348-358.
12. Hollenbach AD, McPherson CJ, Mientjes EJ, Iyengar R, Grosveld G. Daxx and histone deacetylase II associate with chromatin through an interaction with core histones and the chromatin-associated protein Dek. J Cell Sci 2002; 115: 3319-3330.
13. Ko SI, Lee IS, Kim JY, Kim SM, Kim DW, Lee KS et al. Regulation of histone acetyltransferase activity of p300 and PCAF by proto-oncogene protein DEK. FEBS Lett 2006; 580: 3217-3222.
14. Kappes F, Scholten I, Richter N, Gruss C, Waldmann T. Functional domains of the ubiquitous chromatin protein DEK. Mol Cell Biol 2004; 24: 6000-6010.
15. Waldmann T, Eckerich C, Baack M, Gruss C. The ubiquitous chromatin protein DEK alters the structure of DNA by introducing positive supercoils. J Biol Chem 2002; 277: 24988-24994.
16. Wise-Draper TM, Allen HV, Thobe MN, Jones EE, Habash KB, Münger K et al. The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papilloma-virus E7. J Virol 2005; 79: 14309-14317.
17. Fornerod M, van Deursen J, van Baal S, Reynolds A, Davis D, Murti KG et al. The human homologue of yeast CRM1 is in a dynamic subcomplex with CAN/Nup214 and a novel nuclear pore component Nup88. EMBO J 1997; 16: 807-816.
18. Boer J, Bonten-Surtel J, Grosveld G. Overexpression of the nucleoporin CAN/NUP214 induces growth arrest, nucleocytoplas-mic transport defects, and apoptosis. Mol Cell Biol. 1998; 18: 1236-1247.
19. Ageberg M, Gullberg U, Lindmark A. The involvement of cellular proliferation status in the expression of the human proto-oncogene DEK. Haematologica 2006; 91: 268-269.
20. Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C et al. Targeting of the N-terminal coiled coil oligomeriza-tion interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. Int J Cancer 2008; 122: 2744-2752.
21. Zheng X, Seshire A, Rüster B, Bug G, Beissert T, Puccetti E. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haema-tologica 2007; 92: 323-331.
22. Bug G, Gül H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X et al. Valproic acid stimulates proliferation and self-renewal of hema-topoietic stem cells. Cancer Res 2005; 65: 2537-2541.
23. Huntly BJP, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004; 6: 587-596.
24. Coulombel L. Identification of hematopoietic stem/progenitor cells: strength and drawbacks of functional assays. Oncogene 2004; 23: 7210-7222.
25. Deshpande AJ, Cusan M, Rawat VPS, Reuter H, Krause A, Pott C et al. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell 2006; 10: 363-374.
26. Viale A, Franco FD, Orleth A, Cambiaghi V, Giuliani V, Bossi D et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009; 457: 51-56.
27. Guibal FC, Alberich-Jorda M, Hirai H, Ebralidze A, Levantini E, Ruscio AD et al. Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood 2009; 114: 5415-5425.
28. Wojiski S, Guibal FC, Kindler T, Lee BH, Jesneck JL, Fabian A et al. PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. Leukemia 2009; 23: 1462-1471.
29. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol 2005; 15: 494-501.